1-5 of 5
Dolores Hernández
Close
Sort by
Journal Articles

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Laura Rosiñnol, MD, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, Javier Lopez-Jimenez, MD, Javier De La Rubia, MD, Miquel Granell, MD, Juan Besalduch, MD, PhD, Luis Palomera, MD, Yolanda González, MD, Maria Asunción Etxebeste, Joaquín Díaz-Mediavilla, Miguel Teodoro Hernández, Felipe de Arriba, Adrian Alegre, María Teresa Cibeira, Maria Victoria Mateos, MD, PhD, Joaquin Martinez, MD, Juan José Lahuerta, Jesús F San Miguel, Joan Bladé, MD
Journal: Blood
Blood (2012) 120 (21): 334.
https://doi.org/10.1182/blood.V120.21.334.334
Published: 2012
Journal Articles

JAK2 Inhibitor Therapy in Chronic Myeloproliferative Neoplasms Ph(-): Hematologic, Clinical and Molecular Responses

Ana Esther Kerguelen Fuentes, MD, PhD, Dolores Hernández-Maraver, MD, PhD, Miguel Angel, Canales Albendea, MD, PhD, Ana Rodriguez de la Rua, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 5059.
https://doi.org/10.1182/blood.V120.21.5059.5059
Published: 2012
Journal Articles

A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,

Laura Rosiñol, MD, María Teresa Cibeira, Maria Victoria Mateos, Joaquin Martinez, MD, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, Javier López, MD, Javier de la Rubia, Miquel Granell, MD, Juan Besalduch, MD, PhD, Luis Palomera, Yolanda González, MD, Maria Asunción Etxebeste, MD, Joaquín Díaz-Mediavilla, Miguel T Hernández, MD, Felipe de Arriba, Adrian Alegre, Juan José Lahuerta, Jesus F San Miguel, MD PhD, Joan Blade
Journal: Blood
Blood (2011) 118 (21): 3962.
https://doi.org/10.1182/blood.V118.21.3962.3962
Published: 2011
Journal Articles

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

Laura Rosiñol, María Teresa Cibeira, MD, PhD, Maria Victoria Mateos, MD, Joaquin Martinez, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, José García-Laraña, Javier De La Rubia, Anna Sureda, MD, PhD, Juan Besalduch, Luis Palomera, Yolanda Gonzalez, Maria Asunción Etxebeste, Joaquín Díaz-Mediavilla, Miguel T. Hernández, Felipe de Arriba, Adrian Alegre, Juan José Lahuerta, Jesus F San Miguel, Joan Blade
Journal: Blood
Blood (2010) 116 (21): 307.
https://doi.org/10.1182/blood.V116.21.307.307
Published: 2010
Journal Articles

Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade) â /Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade â as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.

Laura Rosiñol, Ma Teresa Cibeira, Joaquin Martinez, Maria Victoria Mateos, Albert Oriol, Ma José Terol, Jose García-Laraña, Dolores Hernández, Javier de la Rubia, Anna Sureda, Juan Besalduch, Luis Palomera, Yolanda Gonzalez, Ma Asuncion Echebeste, Joaquin Díaz-Mediavilla, Felipe de Arriba, Adrian Alegre, Miguel T Hernández, Juan José Lahuerta, J.F F San Miguel, Joan Blade
Journal: Blood
Blood (2009) 114 (22): 130.
https://doi.org/10.1182/blood.V114.22.130.130
Published: 2009